A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 13,100 shares of OCUL stock, worth $134,537. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,100
Previous 33,900 61.36%
Holding current value
$134,537
Previous $308,000 71.1%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.2 - $8.69 $5.74 Million - $11.9 Million
-1,366,739 Reduced 25.21%
4,053,862 $27.7 Million
Q1 2024

May 15, 2024

BUY
$3.85 - $10.93 $7.26 Million - $20.6 Million
1,884,592 Added 53.3%
5,420,601 $49.3 Million
Q4 2023

Feb 14, 2024

BUY
$2.08 - $4.52 $4.67 Million - $10.2 Million
2,246,653 Added 174.25%
3,536,009 $15.8 Million
Q3 2023

Nov 14, 2023

BUY
$3.14 - $5.04 $124,359 - $199,609
39,605 Added 3.17%
1,289,356 $4.05 Million
Q2 2023

Aug 14, 2023

SELL
$4.6 - $7.64 $1.27 Million - $2.11 Million
-276,521 Reduced 18.12%
1,249,751 $6.45 Million
Q1 2023

May 15, 2023

SELL
$2.79 - $6.27 $1.18 Million - $2.64 Million
-421,464 Reduced 21.64%
1,526,272 $8.04 Million
Q4 2022

Feb 14, 2023

BUY
$2.61 - $4.41 $1.45 Million - $2.45 Million
555,311 Added 39.88%
1,947,736 $5.47 Million
Q3 2022

Nov 14, 2022

SELL
$4.09 - $6.5 $1.36 Million - $2.16 Million
-331,568 Reduced 19.23%
1,392,425 $5.78 Million
Q2 2022

Aug 15, 2022

BUY
$3.01 - $5.22 $95,287 - $165,249
31,657 Added 1.87%
1,723,993 $6.93 Million
Q1 2022

May 16, 2022

BUY
$4.83 - $7.35 $779,146 - $1.19 Million
161,314 Added 10.54%
1,692,336 $8.38 Million
Q4 2021

Feb 14, 2022

BUY
$6.16 - $12.07 $9.16 Million - $18 Million
1,487,417 Added 3411.12%
1,531,022 $10.7 Million
Q3 2021

Nov 15, 2021

SELL
$9.7 - $14.34 $1.05 Million - $1.56 Million
-108,645 Reduced 71.36%
43,605 $436,000
Q2 2021

Aug 16, 2021

BUY
$13.43 - $19.16 $593,189 - $846,278
44,169 Added 40.87%
152,250 $2.16 Million
Q1 2021

May 17, 2021

SELL
$15.82 - $22.11 $23.4 Million - $32.7 Million
-1,480,793 Reduced 93.2%
108,081 $1.77 Million
Q4 2020

Feb 16, 2021

SELL
$7.91 - $22.95 $261,733 - $759,392
-33,089 Reduced 2.04%
1,588,874 $32.9 Million
Q3 2020

Nov 16, 2020

BUY
$7.36 - $9.87 $10.3 Million - $13.8 Million
1,401,694 Added 636.36%
1,621,963 $12.3 Million
Q2 2020

Aug 14, 2020

BUY
$4.67 - $8.95 $752,019 - $1.44 Million
161,032 Added 271.84%
220,269 $1.84 Million
Q1 2020

May 15, 2020

BUY
$3.95 - $7.4 $108,269 - $202,834
27,410 Added 86.12%
59,237 $294,000
Q4 2019

Feb 14, 2020

BUY
$2.57 - $4.73 $34,882 - $64,200
13,573 Added 74.36%
31,827 $126,000
Q3 2019

Nov 14, 2019

SELL
$3.04 - $5.32 $5,976 - $10,459
-1,966 Reduced 9.72%
18,254 $55,000
Q2 2019

Aug 14, 2019

SELL
$2.46 - $4.52 $14,474 - $26,595
-5,884 Reduced 22.54%
20,220 $89,000
Q1 2019

May 15, 2019

SELL
$3.51 - $4.77 $135,493 - $184,131
-38,602 Reduced 59.66%
26,104 $0
Q4 2018

Feb 14, 2019

BUY
$3.87 - $7.11 $154,567 - $283,973
39,940 Added 161.27%
64,706 $257,000
Q3 2018

Nov 13, 2018

BUY
$5.42 - $6.99 $23,468 - $30,266
4,330 Added 21.19%
24,766 $0
Q2 2018

Aug 10, 2018

BUY
$5.99 - $8.17 $52,993 - $72,279
8,847 Added 76.34%
20,436 $0
Q4 2017

Feb 09, 2018

BUY
$3.73 - $6.37 $43,226 - $73,821
11,589
11,589 $52,000

Others Institutions Holding OCUL

About OCULAR THERAPEUTIX, INC


  • Ticker OCUL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,966,896
  • Market Cap $790M
  • Description
  • Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...
More about OCUL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.